Cancer Research Technology
Log in Register
Menu

Anti-ΔEGFR [DH8.3]

Info

Catalogue Number 152934
Applications ELISA FACS IHC IP WB
Antigen/Gene or Protein Targets Epidermal growth factor. Truncated EGF receptor (RGFR typeIII/EGFRvIII/deltaEGFR). Recognises an EGFR with truncated extracellular domain, present on human tumours.
Synonyms Avian erythroblastic leukemia viral (v erb b) oncogene homolog, Cell growth inhibiting protein 40, Cell proliferation inducing protein 61, EGF R, EGFR, Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog), Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian), Epidermal growth factor receptor, erb-b2 receptor tyrosine kinase 1, ERBB, ERBB1, Errp, HER1, mENA, NISBD2, Oncogen ERBB, PIG61, Proto-oncogene c-ErbB-1, Receptor tyrosine protein kinase ErbB 1
Reactivity Human
Relevance Monoclonal antibody directed against ΔEGFR, a mutated form of EGFR, typically found in brain tumours. This antibody has use within radiolabelled tumour imaging and potentially therapeutic targeting against ΔEGFR tumours.

Background and Research Application
Epidermal growth factor (EGFR) has attracted considerable attention as a target for cancer therapy. Wild-type EGFR is amplified in a number of cancers, and several mutant forms of the EGFR coding gene have been found. ΔEGFR is the most common mutation, with a deletion of exons 2–7 in the external domain of wt-EGFR, generating a truncated form of EGFR. This ΔEGFR mutation is found in particularly high concentrations within glioblastoma.
Anti-ΔEGFR [DH8.3] is raised to a synthetic peptide that recognises the junctional region of the ΔEGFR receptor. It recognises a genetic rearrangement where exon 1 is spliced to exon 8, resulting in the loss of 801 bp from the mature mRNA. This corresponds to a deletion of 267 amino acids in the receptor’s extracellular domain. The structure of the receptor is then unable to bind ligand, yet is constitutively active, enhancing tumorigenesis due to impaired internalisation and degradation.
Host Mouse
Immunogen Synthetic peptide corresponding to the junctional region of the truncated receptor LEEKKGNYVVTDHC,conjugated to keyhole limpet haemcyanin.
Immunogen UniProt ID P00533
Subclass IgG1 kappa
Myeloma Used NS0
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
Anti-ΔEGFR [DH8.3] does not recognise the natural, wild-type form of EGFR receptor, so therefore does not cross react with the full-length receptor. It only binds cells expressing the mutant receptor. This antibody can be used in tumour imaging, with radiolabelled antibody DH8.3. This antibody has successfully targeted tumours expressing DH8.3 antigen in nude mice. This antibody recognises ΔEGFR in both denatured and native states.

Concentration
1mg/ml as standard
Research Area Cancer, Cell Signaling & Signal Transduction

References

There are 17 reference entries for this reagent.

View All References

References: 17 entries

Genßler et al. 2016. Oncoimmunology. 5(4):e1119354. PMID: 27141401.

Feng et al. 2014. J Clin Invest. 124(9):3741-56. PMID: 25061874.

Feng et al. 2014. J Clin Invest. 124(9):3741-56. PMID: 25061874.

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

Europe PMC ID: 25061874

Feng et al. 2012. Proc Natl Acad Sci U S A. 109(8):3018-23. PMID: 22323579.

Feng et al. 2012. Proc Natl Acad Sci U S A. 109(8):3018-23. PMID: 22323579.

Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.

Europe PMC ID: 22323579

Lammering et al. 2004. Clin Cancer Res. 10(19):6732-43. PMID: 15475464.

IP WB

Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.

Europe PMC ID: 15475464

Nishikawa et al. 2004. Brain Tumor Pathol. 21(2):53-6. PMID: 15700833.

IHC

Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.

Europe PMC ID: 15700833

Jungbluth et al. 2003. Proc Natl Acad Sci U S A. 100(2):639-44. PMID: 12515857.

IHC

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

Europe PMC ID: 12515857

Johns et al. 2002. Int J Cancer. 98(3):398-408. PMID: 11920591.

ELISA FACS

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

Europe PMC ID: 11920591

Hills et al. 1995. Int J Cancer. 63(4):537-43. PMID: 7591264.

Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody.

Europe PMC ID: 7591264


Add a reference

References: 17 entries

Genßler et al. 2016. Oncoimmunology. 5(4):e1119354. PMID: 27141401.

Feng et al. 2014. J Clin Invest. 124(9):3741-56. PMID: 25061874.

Feng et al. 2014. J Clin Invest. 124(9):3741-56. PMID: 25061874.

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

Feng et al. 2012. Proc Natl Acad Sci U S A. 109(8):3018-23. PMID: 22323579.

Feng et al. 2012. Proc Natl Acad Sci U S A. 109(8):3018-23. PMID: 22323579.

Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.

Lammering et al. 2004. Clin Cancer Res. 10(19):6732-43. PMID: 15475464.

IP WB

Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.

Nishikawa et al. 2004. Brain Tumor Pathol. 21(2):53-6. PMID: 15700833.

IHC

Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.

Jungbluth et al. 2003. Proc Natl Acad Sci U S A. 100(2):639-44. PMID: 12515857.

IHC

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

Johns et al. 2002. Int J Cancer. 98(3):398-408. PMID: 11920591.

ELISA FACS

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

Hills et al. 1995. Int J Cancer. 63(4):537-43. PMID: 7591264.

Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody.


Add a reference

Inventor Information